For some special conditions, such as determining HER2 status among patients with advanced cancer or before neoadjuvant therapy, it is necessary to develop some new detection method, or improve the accuracy of CNB, or even IHC itself, by technological innovation or combination with other detection methods. This evidence concerns the gene ERBB2 and cancer.